Welcome to our dedicated page for Rafael Holdings news (Ticker: RFL), a resource for investors and traders seeking the latest updates and insights on Rafael Holdings stock.
Rafael Holdings (RFL) is a diversified holding company focused on clinical stage therapeutics, infusion technology, and strategic real estate. This page serves as your centralized source for official news, press releases, and updates across all business segments.
Access timely announcements on RFL's clinical development programs, mergers, and portfolio expansions. Investors will find critical updates on healthcare investments, infusion technology advancements, and real estate acquisitions. Content includes earnings reports, partnership agreements, and regulatory milestones.
Bookmark this page for direct access to RFL's verified corporate communications. Check regularly for insights into the company's progress in addressing high unmet medical needs and its balanced investment strategy across high-growth and stable sectors.
Rafael Holdings, Inc. (NYSE: RFL) and Rafael Pharmaceuticals presented at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021. Key figures included CEO Ameet Mallik and President Sanjeev Luther. The companies are focused on developing novel cancer therapies, particularly through Rafael Pharmaceuticals, which is advancing multiple clinical studies for its lead drug, CPI-613 (devimistat). This includes ongoing Phase 3 trials for metastatic pancreatic cancer and acute myeloid leukemia. The companies aim to create a publicly traded late-stage clinical oncology entity, enhancing their market position.
Rafael Holdings, Inc. (NYSE: RFL) has announced a merger with Rafael Pharmaceuticals, a late-stage oncology firm specializing in cancer metabolism therapeutics. The merger, unanimously approved by both boards, aims to create a publicly traded company focused on innovative cancer treatments. Key figures include Howard Jonas as Chairman and Ameet Mallik as CEO. The merger includes the acquisition of Altira Capital for $30 million and requires a capital raise of at least $50 million. The lead drug, CPI-613 (devimistat), is in Phase 3 trials for metastatic pancreatic cancer, with results expected in Q4 2021.
Rafael Holdings, Inc. (NYSE: RFL) reported Q3 FY 2021 revenue of $1.0 million, down from $1.2 million year-over-year, primarily due to asset sales and reduced parking revenues amid the COVID pandemic. The loss per share was $0.15, compared to $0.14 in the prior year. The company appointed Ameet Mallik as CEO and William Conkling as Chief Commercial Officer. A shelf registration statement for up to $250 million of Class B common stock was filed. Rafael Pharmaceuticals anticipates pivotal trial data for pancreatic cancer in Q4 2021.
Rafael Holdings, Inc. (NYSE: RFL) announced the appointment of three new members to its Board of Directors: Ameet Mallik, CEO; Shannon Thyme Klinger, Chief Legal Officer of Moderna; and Mark McCamish, CEO of IconOVir Bio. Chairman Howard Jonas expressed optimism, stating the new board members bring significant expertise to advance the company's oncology pipeline. Ameet Mallik highlighted the importance of their industry experience in maximizing the potential of their therapeutics.
Rafael Holdings, Inc. (NYSE: RFL) announced a grant of 908,497 restricted shares of Class B common stock to CEO Ameet Mallik on May 27, 2021, as part of his employment agreement. The shares will vest over the next few years, with initial shares vesting on May 6, 2022, followed by monthly vesting until April 2025. This stock grant was made under the company's 2018 Equity Incentive Plan and approved by the Compensation Committee, serving as an inducement for Mr. Mallik's hiring which took effect on May 1, 2021.
Rafael Pharmaceuticals will present two posters at the 2021 ASCO Annual Meeting from June 4-8, discussing trials on devimistat for pancreatic and biliary tract cancers. Presentation Abstract #TPS4158 explores the efficacy of gemcitabine and cisplatin, while Abstract #TPS4176 focuses on devimistat paired with (m)FOLFIRINOX. Sanjeev Luther, the company’s President, emphasizes significant advancements despite challenges. Devimistat, a first-in-class compound, targets cancer cell metabolism, showing promise for future cancer treatments.
Rafael Holdings, Inc. (NYSE: RFL) announced an inducement grant on April 15, 2021, to Chief Commercial Officer William Conkling for options to purchase 118,409 shares of Class B common stock. The exercise price is set at $40.85, reflecting the closing price on the previous trading day. The options will vest over a period, starting with 29,602 on April 15, 2022, followed by monthly vesting. This grant is part of Rafael's 2018 Equity Incentive Plan, designed to attract key talent while adhering to NYSE Rule 303A.08.
Rafael Pharmaceuticals has announced the enrollment of over 150 patients in its Phase 3 clinical trial (ARMADA 2000) for relapsed or refractory acute myeloid leukemia (AML). This multicenter trial evaluates the efficacy of CPI-613® (devimistat) in combination with specific chemotherapy drugs. The company recently achieved FDA fast-track designation for this treatment, highlighting its potential in addressing the urgent need for effective AML therapies. Experts emphasize the significance of this milestone in improving outcomes for patients suffering from this challenging cancer.
Rafael Holdings, Inc. (NYSE: RFL) reported Q2 FY 2021 revenue of $1.0 million, down from $1.2 million year-over-year, primarily due to the sale of a building. Loss per share increased to $0.50, influenced by a $7.0 million impairment related to Altira. Ameet Mallik will assume the CEO role on May 1, 2021. The firm holds 51% of Rafael Pharmaceuticals, which has received FDA Fast Track designation for its lead compound, CPI-613® (devimistat), aimed at treating various cancers. The company continues its focus on oncology through strategic investments and partnerships.
Rafael Holdings, Inc. (NYSE: RFL) has appointed Ameet Mallik as its new Chief Executive Officer, effective May 1, 2021, succeeding founder Howard Jonas who remains Chairman. Bill Conkling joins as Chief Commercial Officer on March 15, 2021. Mallik, previously from Novartis, brings extensive experience in oncology, crucial as Rafael conducts multiple clinical studies. The leadership expansion aims to enhance the company's ability to develop innovative cancer therapies across its subsidiaries, including Rafael Pharmaceuticals and LipoMedix.